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Does desmopressin acetate reduce blood loss after
surgery in patients on cardiopulmonary bypass?
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ABSTRACT It has been suggested that desmopressin acetate (DDAVP) administration reduces blood
loss after cardiac surgery. We have investigated the effect ofDDAVP administration in a double-blind,
randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during sur-
gery. Fifty patients received 0.3 gg/kg DDAVP and 50 patients received a placebo administered in a 50
ml saline solution over 15 min when cardiopulmonary bypass had been concluded. Results showed no
significant differences either in total blood loss per square meter (458 + 206 ml in the DDAVP group
vs 536 ± 304 ml in the placebo group) or in necessity for red cell transfusions (1642 ± 705 ml in the
DDAVP group vs 1574 ± 645 ml in the placebo group) in the first 72 hr after surgery. Only
intraoperative blood loss per square meter was significantly lower (p < .02) in the DDAVP group (131
+ 106 ml) as compared with the placebo group (193 + 137 ml). The prolongation of bleeding time and
the decrease of factor VIII: C and factor VIII: von Willebrand factor 90 min after treatment were
significantly lower (p < .001) in the DDAVP group as compared with the placebo group. We conclude
that the administration of DDAVP in patients placed on cardiopulmonary bypass during surgery does
not reduce total blood loss and is only elfective in reducing intraoperative bleeding.
Circulation 77, No. 6, 1319-1323, 1988.
PATIENTS placed on cardiopulmonary bypass (CPB)
for open heart surgery have an increased susceptibility
to postoperative bleeding.' Reoperation for bleeding
control is sometimes necessary and occasionally life-
threatening hemorrhaging occurs during the postoper-
ative period. The majority of patients bleed primarily
from the operative site. However, in some patients,
diffuse systemic bleeding2'3 suggests an acute acquired
hemostatic defect. The basic pathophysiology of al-
tered hemostasis associated with CPB remains confus-
ing. The abnormalities most frequently found include
heparin and protamine excess, heparin rebound, low
platelet count, abnormal platelet function, low fibrino-
gen, primary fibrinolysis, and disseminated intravas-
cular coagulation.4"'6
Since a significant platelet function defect may be
the primary cause of hemorrhage, the use of platelet
concentrateN and prostacyclin has been suggest-
ed.2', 17, A defect in ristocetin-induced platelet aggre-
gation has been described in these patients,2 suggesting
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a role for von Willebrand factor in the hemostatic de-
fect.'9 Recently, Salzman et al.20 showed that des-
mopressin acetate (DDAVP) reduced postoperative
blood loss in patients undergoing CPB. They suggest-
ed that the elevation in the plasma concentration of von
Willebrand factor induced by DDAVP, possibly in
association with a change in the distribution of von
Willebrand factor multimers, was the most likely ex-
planation for the beneficial effect of the drug in CPB.
However, it has been argued that the good results
found by Salzman et al. may be related to the high
postoperative blood loss reported in their patients.21 22
DDAVP is a synthetic analog of the neurohypophys-
eal nonapeptide arginine vasopressin. It is known that
this hormone causes the appearance of larger von
Willebrand's factor multimers in addition to increased
concentrations of factor VIII: von Willebrand factor
and factor VIII: C and thus a role for DDAVP has been
indicated in patients with mild hemophilia or von Wil-
lebrand's disease.23 DDAVP has also been shown to
shorten the bleeding time in other conditions, includ-
ing uremia, chronic liver disease, and aspirin inges-
tion. 24-26
In the present study we evaluated the effectiveness
of intraoperative DDAVP in the reduction of blood
loss during the postoperative period in a double-blind,
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randomized, prospective trial involving 100 patients
placed on CPB during surgery.
Methods
Study population. To be eligible for recruitment, patients
had to satisfy the following inclusion criteria: age over 18 years
and valvular heart disease or atrial septal defects. Patients were
excluded for the following reasons: emergency surgery, known
hemostatic defect, uncontrolled hypertension, and renal insuffi-
ciency. Patients undergoing coronary artery bypass grafting
were also excluded on the basis of a possible hypercoagulable
state secondary to an increase of von Willebrand factor due to
administration of DDAVP.
Study design. The protocol was approved by our hospital's
Clinical Assays Committee. After obtaining informed consent,
a prospective double-blind, randomized trial involving 100 pa-
tients was begun. Patients were randomly assigned to one of the
following groups: (1) Fifty patients received DDAVP, 0.3
,g/kg body weight, maximum 20 ,g (kindly supplied by Fer-
ring Pharmaceuticals, Malmoe, Sweden). (2) Fifty patients re-
ceived a placebo similar in appearance to the drug.
On completion of CPB and immediately after administration
of protamine, treatment was administered intravenously in a 50
ml solution for 15 min.
Methods of data analysis. Blood samples were obtained
before operation, immediately before treatment was started,
90 min after administration of treatment, and 24 hr post-
operatively.
The following measurements were obtained in all samples.
Hematocrit, hemoglobin, and platelet count were measured
with a Coulter S Plus II. Factor VIII:C was determined as
described by Hardisty and McPherson.27 Factor VIII: von Wil-
lebrand factor was measured by an ELISA method (Boehringer
Mannheim, Mannheim, W. Germany). Bleeding time was de-
termined by the Simplate H technique (General Diagnostics,
New Jersey)28 before operation and 90 min after administration
of treatment.
Intraoperative blood loss starting at the time of treatment
administration and postoperative blood loss in the first 72 hr
were measured by weighing sponges and measurement of drain-
ages. Red cell transfusions in the first 3 postoperative days were
recorded. Blood pressure and urine output in the first 24 hr were
measured.
Statistical methods. Results are expressed as the mean ±
SD. Student's t test was used to compare mean values, and
Student's t test for paired observations was used to compare the
mean value of the same variable at different times. Comparison
of proportions was performed according to Fisher's exact test.
Results
One hundred eligible patients consented to partici-
pate in this trial. The baseline characteristics, the main
diagnoses, and types of surgery are listed in table 1.
There were no significant differences with regard to
any of the characteristics analyzed between the two
groups of patients.
Determinations of hematocrit, hemoglobin, platelet
count, factor VIII: C, and factor VIII: von Willebrand
factor before surgery, immediately before and 90 min
after administration of treatment, and 24 hr postopera-
tively are indicated in figure 1. Bleeding time before
surgery and 90 min after therapy is also shown. Preop-
TABLE 1
Characteristics of the two groups of patients
Characteristic DDAVP Placebo
Age (years) 55 ± 13 53±+ 12
Sex (male/female) 19/31 25/25
Body surface area (m2) 1.7 ±0.1 1.7±0.1
Principal diagnosis
Mitral stenosis 9 9
Mitral regurgitation 4 2
Double mitral lesion 10 13
Aortic stenosis 4 6
Aortic regurgitation 6 0
Double aortic lesion 6 12
Atrial septal defect 4 1
Double mitral and double aortic lesion 3 3
Mitral and aortic regurgitation 0 1
Double mitral and double tricuspid lesion 1 0
Double mitral lesion and tricuspid
regurgitation 2 0
Mitral and tricuspid regurgitation 1 0
Mitral stenosis and tricuspid regurgitation 01
Double mitral and aortic lesion plus
tricuspid regurgitation 0 2
Operative procedure
Mitral valve replacement 19 16
Mitral commissurotomy 4 6
Mitral anuloplasty 0 2
Aortic valve replacement 16 18
Mitral and aortic valve replacement 3 4
Mitral valve replacement and tricuspid
anuloplasty 4 1
Mitral and aortic valve replacement plus
tricuspid anuloplasty 0 2
Closure of atrial septal defect 4 1
Duration of extracorporeal circulation (min) 93 ±43 94 +40
No significant differences between groups were observed.
eratively, the mean values were similar in both groups,
with no significant differences. There was a significant
decline (p < .0001) in hematocrit and hemoglobin in
blood samples obtained immediately before treatment
compared with the basal value, and this was similar in
both groups. Both variables recovered 24 hr after sur-
gery. A significant decrease (p < .0001) in platelet
count compared with the basal value, without changes
during the first 24 hr of the postoperative period, was
observed in both groups.
In the placebo group there was a significant decrease
in factor VIII: C (p < .001) immediately before treat-
ment (0.94 0.06 U/ml) compared with the basal
value (1.29 0.08 U/ml). A similar decline was ob-
served in the blood sample obtained 90 min after treat-
ment (0.96 + 0.07 U/ml); the value returned to normal
24 hr after surgery (1.16 + 0.06 U/ml).
In the DDAVP group there was a decrease in factor
VIII: C similar to that observed in the placebo group
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FIGURE 1. Evolution of hematocrit, hemoglobin, platelet count,
bleeding time, factor VIII: C, and factor VIII: vWF in blood samples
obtained before operation (A), immediately before (B) and 90 min after
(C) treatment, and 24 hr postoperatively (D) in patients treated with
DDAVP ( ) or placebo ( -- ). The mean SEM is reported. *p <
.001 as compared with the control group.
immediately before infusion (0.83 0.06 U/ml); the
differences were significant (p < .001) compared with
the basal value (1.23 ± 0.07 U/ml). However, 90 min
after therapy there was a marked increase in factor
VIII: C (1.62 ± 0.12 U/ml), with a significant differ-
ence compared with the basal value (p < .005) and
with the same value in the placebo group (p < .001).
As shown in figure 1, modifications similar to those
described for factor VIII: C were observed for factor
VIII:von Willebrand factor.
Bleeding time showed a marked prolongation in the
placebo group 90 min after administration of treatment
(13.8 ± 1.1 min) compared with the basal value (5.9
± 0.3 min; p < .001). DDAVP therapy partially cor-
rected the prolongation of bleeding time at 90 min of
infusion (9.4 ± 0.7 vs 5.6 ± 0.4 min before surgery)
and there was a significant difference compared with
the value for the placebo group (p < .001).
Results of blood loss and red cell transfusions are
shown in table 2. Total blood loss per square meter in
the first 72 hr was 536 ± 304 ml in the placebo group
and 458 + 206 ml in the DDAVP group; this differ-
ence was not significant. Therefore, no differences in
blood loss in the first 24 hr were observed between
groups. Only intraoperative blood loss was significant-
ly lower (p < .02) in the DDAVP group (131 ± 106
ml) than in the placebo group (193 + 137 ml). One
patient in the placebo group required surgical reopera-
tion to control hemorrhaging. The volume of red cell
transfused in the first 3 days was similar in both
groups.
No correlation between bleeding time, factor
VIII:C, and factor VIII:von Willebrand factor and
total blood loss was observed in the samples obtained
preoperatively and 90 min after treatment. In the sam-
ple obtained 90 min after administration of treatment a
significant correlation between factor VIII: C and in-
traoperative blood loss was found (r = -.36, p <
.001). However, no correlation of intraoperative blood
loss with bleeding time and factor VIII:von Wille-
brand factor could be demonstrated in this sample.
As shown in table 2, DDAVP therapy provoked no
complications either in regard to blood pressure or
urine output. No deaths or severe complications oc-
curred intraoperatively or on the first 3 postoperative
days in any patients included in the study.
Discussion
Patients undergoing cardiac surgery under CPB are
known to have increased blood loss intra- and postop-
eratively. Excessive hemorrhaging occasionally re-
quires reoperation. Recently Salzman et al., in a dou-
TABLE 2
Results of the study
DDAVP Placebo
Blood loss/m2 (ml)
Intraoperative 131 + 106 193 ± 137A
0-24 hr 249± 144 253±224
24-72 hr 78±58 89±89
Total 458 ± 206 536 ± 304
Red cell transfusions (ml)
0-24 hr 1366±561 1352±418
24-72 hr 276 ±494 222 ± 430
Total 1642 ±705 1574 ± 645
Blood pressure (mm Hg)
High 134± 29 122 ± 38
Low 75±16 73±12
Urinary output in 24 hr (ml) 2437 ± 857 2329 ± 616
Ap < .02.
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ble-blind, randomized trial, concluded that DDAVP
effectively reduced blood loss and transfusion require-
ments in these patients,20 thus confirming results of a
previous clinical nonrandomized trial carried out by
Czer et al.29 However, Salzman's study has been criti-
cized because his patients had suffered excessive blood
loss .22
The objective of our study was to confirm the effica-
cy of DDAVP in reducing blood loss and transfusion
requirements in patients undergoing surgery under
CPB in a double-blind, randomized, prospective trial
involving 100 patients. In our study the administration
of DDAVP significantly reduced the postoperative
prolongation of bleeding time and avoided the de-
crease in plasmatic levels of factor VIII: C and factor
VIII: von Willebrand factor and even increased these
levels. Similar results with the same drug have been
obtained under other clinical conditions23"26 and are in
agreement with Salzman's data.20
In spite of these reported analytic changes we cannot
confirm that DDAVP reduces total blood loss and
transfusion requirements, although it was observed to
significantly reduce intraoperative blood loss.
The characteristics of the patients included in our
study were similar with respect to age, sex, diagnosis,
and operative procedure to those in Salzman's study,
except that in his previous study, a small patient group
with coronary artery disease, known to have high peri-
operative bleeding complications, was included and
the duration of extracorporeal circulation was longer.
Thus, it seems unlikely that differences in characteris-
tics of the patients in the studies are responsible for the
disparate findings.
Unlike Salzman's study, which measured total
blood loss, we evaluated the blood loss in relation to
body surface, which in our experience is a more exact
and objective determination. On the other hand, blood
loss observed in both groups was considerably less in
our study, which supports Allen's criticism com-
22ment.
In Salzman's study a correlation between the preop-
erative plasma level of factor VIII:von Willebrand
factor and subsequent blood loss was shown. We
found no significant correlation of blood loss with pre-
operative factor VIII:C, factor VIII:von Willebrand
factor, or bleeding time. The significant correlation
between intraoperative blood loss and factor VIII:C
levels 90 min after treatment suggests that this reduc-
tion might be related to an increase in factor VIII:C
induced by DDAVP. In spite of the lack of demonstra-
ble correlation between intraoperative blood loss and
factor VIII: von Willebrand factor in the sample ob-
1322
tained 90 min after treatment, a reduction in such a loss
due to a change in the distribution of von Willebrand
factor multimers secondary to DDAVP administration
cannot be excluded.
We conclude that the administration of DDAVP in
patients placed on CPB for surgery for valvular heart
disease or atrial septal defect does not reduce total
blood loss and is only effective in reducing intraopera-
tive bleeding. Taking into account its lack of side ef-
fects, we would recommend use of this drug in patients
with excessive intraoperative hemorrhage.
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